Qualigen granted patents for QN-302 covering 25 countries through 2040

AIxCrypto Holdings, Inc.

Patents for QN-302 granted in over 20 European countries plus India, China, and Russia.
Patent titled 'Substituted Naphthalene Diimides and Their Use' covers product and manufacturing methods.
Expiration extends to 2040; drug targets pancreatic and gastrointestinal cancers.
Qualigen licensed QN-302 from University College of London (Prof. Stephen Neidle).
CEO states patent coverage strengthens position as drug development company.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.